{
    "title": "112_hr4332",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Generic Drug Application Review \nFairness Act of 2012''.\n\nSEC. 2. EXTENSION OF PERIOD FOR FIRST APPLICANT TO OBTAIN TENTATIVE \n              APPROVAL WITHOUT FORFEITING 180-DAY EXCLUSIVITY PERIOD.\n\n    (a) Extension of Period.--\n            (1) In general.--Subclause (IV) of section 505(j)(5)(D)(i) \n        of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n        355(j)(5)(D)(i)) is amended to read as follows:\n                                    ``(IV) Failure to obtain tentative \n                                approval.--The first applicant fails to \n                                obtain tentative approval of the \n                                application within 60 months after the \n                                date on which--\n                                            ``(aa) the application is \n                                        filed and initially contains a \n                                        certification described in \n                                        paragraph (2)(A)(vii)(IV), or\n                                            ``(bb) the application is \n                                        amended to first contain such a \n                                        certification,\n                                unless the failure is caused by a \n                                change in or a review of the \n                                requirements for approval of the \n                                application imposed after the date on \n                                which the application is so filed or \n                                amended.''.\n            (2) Applicability.--\n                    (A) In general.--Subject to subsection (b), the \n                amendment made by paragraph (1) applies--\n                            (i) only with respect to an application \n                        that is filed under section 505(j) of the \n                        Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n                        355(j)) on or after the day that is 30 months \n                        prior to the date of the enactment of this Act; \n                        and\n                            (ii) only if no certification under \n                        paragraph (2)(A)(vii)(IV) of such section \n                        505(j) was made before such day with respect to \n                        the listed drug (as such term is used in such \n                        section 505(j)).\n                    (B) Certain applications.--If an application was \n                filed under section 505(j) of the Federal Food, Drug, \n                and Cosmetic Act (21 U.S.C. 355(j)) prior to the day \n                specified in subparagraph (A)(i) and, on such day, \n                contained a certification described in paragraph \n                (2)(A)(vii)(IV), the application shall be subject to \n                paragraph (5)(D)(i)(IV) of such section 505(j) as in \n                effect on the day before the date of the enactment of \n                this Act.\n    (b) Incremental Reduction of Extended Period.--\n            (1) Period duration.--\n                    (A) Effective on October 1, 2013, subclause (IV) of \n                section 505(j)(5)(D)(i) of the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)), as amended by \n                subsection (a)(1), is amended by striking ``60 months'' \n                and inserting ``54 months''.\n                    (B) Effective on October 1, 2014, subclause (IV) of \n                section 505(j)(5)(D)(i) of the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)), as amended by \n                subparagraph (A), is amended by striking ``54 months'' \n                and inserting ``48 months''.\n                    (C) Effective on October 1, 2015, subclause (IV) of \n                section 505(j)(5)(D)(i) of the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)), as amended by \n                subparagraph (B), is amended by striking ``48 months'' \n                and inserting ``42 months''.\n                    (D) Effective on October 1, 2016, subclause (IV) of \n                section 505(j)(5)(D)(i) of the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)), as amended by \n                subparagraph (C), is amended by striking ``42 months'' \n                and inserting ``36 months''.\n                    (E) Effective on October 1, 2017, subclause (IV) of \n                section 505(j)(5)(D)(i) of the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)), as amended by \n                subparagraph (D), is amended by striking ``36 months'' \n                and inserting ``30 months''.\n            (2) Applicability.--\n                    (A) The amendments made by subparagraphs (A), (B), \n                (C), and (D) of paragraph (1) apply only with respect \n                to an application under section 505(j) of the Federal \n                Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) that--\n                            (i) is filed and initially contains a \n                        certification described in paragraph \n                        (2)(A)(vii)(IV) during the period of one fiscal \n                        year beginning on the effective date of the \n                        respective amendment; or\n                            (ii) is amended to initially contain such a \n                        certification during such period.\n                    (B) The amendment made by paragraph (1)(E) applies \n                only with respect to an application under section \n                505(j) of the Federal Food, Drug, and Cosmetic Act (21 \n                U.S.C. 355(j)) that--\n                            (i) is filed and initially contains a \n                        certification described in paragraph \n                        (2)(A)(vii)(IV) on or after October 1, 2017; or\n                            (ii) is amended to initially contain such a \n                        certification on or after October 1, 2017.\n    (c) Conforming Amendment.--Subparagraph (G) of section 505(q)(1) of \nthe Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(q)(1)) is \namended by striking ``the 30-month period'' and inserting ``the \nperiod''.\n\nSEC. 3. MAINTENANCE OF OFFICE OF GENERIC DRUGS AT CDER; REPORTING.\n\n    Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 355(j)) is amended by adding at the end the following:\n            ``(11) Office of generic drugs.--\n                    ``(A) Office.--The Secretary shall maintain the \n                Office of Generic Drugs as a separate office within the \n                Center for Drug Evaluation and Research of the Food and \n                Drug Administration.\n                    ``(B) Reporting.--The Director of the Office of \n                Generic Drugs shall report directly to the Director of \n                the Center for Drug Evaluation and Research.''."
}